Buffalo Biolabs, LLC
- UEI
- VXHYLVGRCRK7
- CAGE
- 5FMY9
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| A novel TLR5 agonist-based adjuvant for poliovirus vaccine | National Institute of Allergy and Infectious Diseases | $581,198 | |
| Deimmunized TLR5 agonist for anticancer therapy | National Institutes of Health | $223,303 | |
| Testing of novel anti-cancer compounds curaxins against pancreatic cancer | National Institutes of Health | $479,664 | |
| SUV39H targeted therapy for treatment of childhood rhabdomyosarcoma | National Institutes of Health | $100,000 | |
| Other functions r & d - medical biomedical (basic research) | National Cancer Institute | $200,000 |
Quick answers
What is Buffalo Biolabs, LLC's UEI?
Buffalo Biolabs, LLC's Unique Entity ID (UEI) in SAM.gov is VXHYLVGRCRK7.
What is Buffalo Biolabs, LLC's CAGE code?
Buffalo Biolabs, LLC's CAGE code is 5FMY9.
What is Buffalo Biolabs, LLC's primary NAICS code?
Buffalo Biolabs, LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Buffalo Biolabs, LLC registered in SAM.gov?
Buffalo Biolabs, LLC's SAM.gov registration expired on January 20, 2023.
What is Buffalo Biolabs, LLC's most recent federal award?
Buffalo Biolabs, LLC's most recent federal grant award is A novel TLR5 agonist-based adjuvant for poliovirus vaccine (R43AI126979), from National Institute of Allergy and Infectious Diseases, on July 1, 2016.
On GovTribe
See Buffalo Biolabs, LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors